This session highlights emerging strategies to slow chronic kidney disease progression and protect cardiovascular health in people with diabetes (both type 1 and type 2) and hypertension. Leading experts review the complementary roles of SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists and incretin-based therapies in achieving durable cardiorenal protection, and highlight next-generation aldosterone pathway inhibitors and other novel agents in development for chronic kidney disease. They also interpret new data on finerenone in type 1 diabetes–associated kidney disease, translating these advances into practical guidance for contemporary, guideline-directed care.